HPLC purity ≥ 99%
Janoshik CoA per batch
Stable lyophilised storage
Dispatched within 24 h from the EU
Research reagents — RUO
Full batch number traceability
Secure & discreet payment
HPLC purity ≥ 99%
Janoshik CoA per batch
Stable lyophilised storage
Dispatched within 24 h from the EU
Research reagents — RUO
Full batch number traceability
Secure & discreet payment
HPLC purity ≥ 99%
Janoshik CoA per batch
Stable lyophilised storage
Dispatched within 24 h from the EU
Research reagents — RUO
Full batch number traceability
Secure & discreet payment
HPLC purity ≥ 99%
Janoshik CoA per batch
Stable lyophilised storage
Dispatched within 24 h from the EU
Research reagents — RUO
Full batch number traceability
Secure & discreet payment
← Notebook
Science· 6 min read

PT-141 (Bremelanotide): a melanocortin analog refined for MC4R/MC3R selectivity

Derived from Melanotan II but designed to reduce the pigmentary effect, PT-141 illustrates the logic of receptor selectivity in melanocortin pharmacology.

PT-141 (Bremelanotide) is a cyclic heptapeptide derived from Melanotan II, designed to refine receptor selectivity within the melanocortin family.

A derivative designed to reduce the pigmentary effect

Melanotan II non-selectively activates all four melanocortin receptors (MC1R, MC3R, MC4R, MC5R). PT-141 was developed from this structure to display increased selectivity toward MC4R and MC3R, with reduced affinity for MC1R — the receptor responsible for the skin pigmentary effect. This modification illustrates a classic approach in pharmacology: isolating a mechanism of interest by reducing activity on non-targeted receptors.

A central action on hypothalamic neurons

The literature (PMID 18684229, PMC5310636) characterizes an activation of pro-opiomelanocortin neurons in the hypothalamic paraventricular nucleus, modulating the central release of nitric oxide and dopamine. This central mechanism distinguishes PT-141 from classic peripheral vasoactive compounds.

A profile with no documented systemic vascular effect

A point highlighted by the literature: unlike vasoactive molecules that act directly on blood vessels, PT-141 acts centrally without significantly altering systemic blood pressure at the doses studied — an important pharmacological distinction in the characterization of this compound.

Copulatory behavior and satiety: two axes of study

Preclinical work describes a stimulation of copulatory behavior in animal models, as well as an effect on satiety via the MC4R-leptin pathway — the latter being shared with other non-selective melanocortin agonists such as Melanotan II.

Placing PT-141 within the melanocortin family

PT-141 completes a set of three melanocortin ligands of increasing selectivity studied in our catalog: Melanotan I (MC1R-selective), Melanotan II (non-selective) and PT-141 (MC4R/MC3R-selective) — a useful triptych for comparative research on the contribution of each sub-receptor.

To go further